Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21780689 | 0.91 | HCAR3 (0.46) | HCAR3ARAOC3CRHR1DRD2 | |
| SCHEMBL16646632 | 0.83 | HCAR3 (0.44) | HCAR3MKNK1ARALDH1A1LMNA | |
| SCHEMBL9924584 | 0.75 | GBA1 (0.48) | ALDH1A1LMNAAOC3CRHR1 | |
| SCHEMBL16748981 | 0.75 | LMNA (0.38) | HCAR3MKNK1ALDH1A1LMNAPOLB | |
| SCHEMBL16132278 | 0.71 | SLC29A1 (0.40) | HCAR3MKNK1POLBCRHR1SLC29A1 | |
| SCHEMBL21769443 | 0.71 | HCAR3 (0.33) | HCAR3 | |
| SCHEMBL16002391 | 0.71 | LMNA (0.41) | HCAR3MKNK1ALDH1A1LMNAPOLB | |
| SCHEMBL13335930 | 0.71 | HCAR3 (0.50) | HCAR3MKNK1ARAOC3TACR1 | |
| SCHEMBL17484101 | 0.69 | KCNH2 (0.46) | HCAR3MKNK1ALDH1A1LMNADRD3 | |
| SCHEMBL20056973 | 0.67 | HCAR3 (0.57) | HCAR3ARALDH1A1AOC3CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359365-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HCAR3 1132/4885MKNK1 122/4885AR 2978/4885 |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HCAR3 1132/4885MKNK1 122/4885AR 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.